NONE 20260624104322907 wseas/wseas content-registration-form@crossref.org content-registration-form PROOF 2944-9162 2732-9941 Hasan Keleş Department of Mathematics Karadeniz Technical University Campus of Kanuni, Ortahisar, 61080 Trabzon TURKIYE Umit Yavuz Keleş Department of Gastroenterology Karadeniz Technical University Campus of Kanuni, Ortahisar, 61080 Trabzon TURKIYE 06 24 2026 06 24 2026 36 5 https://creativecommons.org/licenses/by/4.0/deed.en_US 10.37394/232020.2026.6.5 https://wseas.com/journals/proof/2026/a10proof-005(2026).pdf Kele, H., & Kele, U. Y. (2026). Strategic Decision Support System Using Triple Logic for Hepatocellular Carcinoma in Cirrhosis. International Journal of Oncology and Cancer Therapy (IARAS), vol. 6, pp. 1–12. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229263. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022;400(10360):13451362. Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2022;19(3):151172. Lee YT, Fujiwara N, Yang JD, Hoshida Y. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology 2023;78(1):319362. Wei H, Dong C, Li X. Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future. J Clin Transl Hepatol 2024;12(4):389405. Zheng X, Liu X, Lei Y, Wang G, Liu M. Glypican-3: A novel and promising target for the treatment of hepatocellular carcinoma. Front Oncol 2022;12:824208. Devan AR, Nair B, Pradeep GK, Alexander R, Vinod BS, Nath LR, et al. The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential. Eur J Med Res 2024;29(1):490. Zhou F, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev 2018;38(2):741767. Nishida T, Kataoka H. Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers (Basel) 2019;11(9):1339. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64(7):24182423. Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. β-Catenin signaling in hepatocellular carcinoma. J Clin Invest 2022;132(4):154515. Cheng K, Cai N, Zhu J, Yang X, Liang H, Zhang W. Tumor-associated macrophages in liver cancer: From mechanisms to therapy. Cancer Commun (Lond) 2022;42(11):11121140. Yeo YH, Lee YT, Tseng HR, Zhu Y, You S, Agopian VG, et al. Alpha-fetoprotein: Past, present, and future. Hepatol Commun 2024;8(5):0422. Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013;19(4):920928. Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: Results of phase I trials. Clin Cancer Res 2020;26(15):39793989.